| Website | naurex.com |
| Category | BioTech |
| Phone | 847-871-0377 |
| corporate@naurex.com | |
| Employees |
| TOTAL | $56M |
| FUNDING TOTAL | $56M |
| Series A, 5/11 Adams Street Partners Latterell Venture Partners Druid BioVentures Genesys Capital PathoCapital Takeda Ventures | $18M |
| Series B, 12/12 Baxter Ventures Savitr Capital Adams Street Partners Latterell Venture Partners Genesys Capital PathoCapital Druid BioVentures | $38M |
Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs), which modulate the receptor in a different way than existing NMDAR agents. The company’s drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex’s platform of novel NMDAR modulators.
